Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US

Ralph P. Insinga, David J. Vanness, Josephine L. Feliciano, Kristel Vandormael, Sory Traore, Thomas Burke

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences